We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Zimmer Completes Offer for Centerpulse

By HospiMedica staff writers
Posted on 15 Oct 2003
Stating that it is now the leading "pure-play” orthopedics company in the world, Zimmer Holdings, Inc. More...
(Warsaw, IN, USA) has announced the closing of its offer for Centerpulse AG (Zurich, Switzerland).

As a result of the exchange offer, Zimmer now owns 98.7% of the issued Centerpulse shares and 99.9% of the issued shares held by InCentive Capital AG, which owned 18.3% of Centerpulse shares. Zimmer intends to promptly initiate the process to acquire all of the shares that remain outstanding, thereby concluding an offer that began in May 2003 when the company first announced its offer of around US$3.1 billion for Centerpulse.

The transaction creates a company with combined 2002 sales of more than $2 billion; more than 100,000 products in the reconstructive, trauma, spine, dental, and orthopedic surgery areas; and more than 1,000 patents. Zimmer estimates that about 25% of its sales will be generated in Europe. The addition of Centerpulse bolsters Zimmer's presence in Europe, while complementing its market strengths in the USA and the Japan/Asia Pacific regions.

"This strategic transaction solidifies our industry leadership and creates a powerful engine for future growth with exceptional research and development capabilities; a dedicated and culturally diverse work force; and venders, partners, and sales representatives worthy of envy. Patient quality of life and a passion to win will continue to guide us,” said Ray Elliot, chairman, president, and CEO of Zimmer.





Related Links:
Zimmer
Centerpulse

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Medical-Grade Display
HL2316SHTB
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: 123RF

Existing Cardiovascular Risk Calculators Predict Several Common Cancers

Cardiovascular risk calculators are embedded in primary and secondary care to estimate 10‑year risk of heart attack or stroke from factors such as age, body mass index, and smoking. Many of these same... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.